Supplementary material for the following manuscript:

Title
The Epidemiology of Myasthenia Gravis in Denmark, Finland, and Sweden: A Population-Based Observational Study

Authors
John Vissing¹, Sari Atula², Mari Savolainen³, Juha Mehtälä⁴, Laila Mehkri⁵, Tina Bech Olesen⁵, Tero Ylisaukko-oja⁴,⁵, Ingrid Lindberg-Schager⁶, Fredrik Berggren⁷, Fredrik Piehl⁸,⁹

Affiliations
¹Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
²Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;
³UCB Pharma, Espoo, Finland;
⁴MedEngine Oy, Helsinki, Finland;
⁵MedEngine DK ApS, Copenhagen, Denmark;
⁶UCB Pharma, Stockholm, Sweden;
⁷UCB Pharma, Copenhagen, Denmark;
⁸Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;
⁹Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
**SUPPLEMENTARY FIGURES**

**Supplementary Figure 1. Flow-chart of the study population.**

- **Full Primary Cohort (FPC)**
  - All patients with ≥1 MG diagnosis in 2000–2020:
    - DK N=2,984
    - FI N=2,653
    - SE N=5,499

- **Prevalent Sub-Cohort (PSC)**
  - All patients with ≥2 MG diagnoses in 2000–2020:
    - DK N=2,248
    - FI N=2,306
    - SE N=4,500

- **Incident Sub-Cohort (ISC)**
  - All patients with ≥2 MG diagnoses in 2000–2020 and no MG diagnosis prior to 1 Jan 2000:
    - DK N=1,559
    - FI N=1,797
    - SE N=3,059

FPC, Full primary cohort; PSC, Prevalent Sub-Cohort; ISC, Incident Sub-Cohort; DK, Denmark; FI, Finland; SE, Sweden.

* A minimum of 12 months without an MG diagnosis before the date of diagnosis was required for a patient to be included in the incident cohort (prior MG diagnosis was screened from all available registry data).
Supplementary Figure 2. Incidence of myasthenia gravis per 100,000 in the Incident Sub-Cohort in Denmark, Finland, and Sweden in year 2000–2020, as stratified by age and sex.

DK, Denmark; FI, Finland; SE, Sweden.
Supplementary Figure 3. Prevalence of myasthenia gravis in the Prevalent Sub-Cohort in Denmark, Finland, and Sweden in year 2000–2020, as stratified by age and sex.

DK, Denmark; FI, Finland; SE, Sweden.
Supplementary Figure 4. Standardised mortality ratio of myasthenia gravis in the Prevalent Sub-Cohort in Denmark, Finland, and Sweden in 2000–2020 compared to the background population, as stratified by age and sex.

DK, Denmark; FI, Finland; SE, Sweden.